Biological agents for moderately to severely active ulcerative colitis: a systematic review and network meta-analysis.
about
The clinical potential of etrolizumab in ulcerative colitis: hypes and hopesAdvances in the development of new biologics in inflammatory bowel diseaseThe role of vedolizumab in patients with moderate-to-severe Crohn's disease and ulcerative colitisPromising biological therapies for ulcerative colitis: A review of the literatureVedolizumab: an α4β7 integrin antagonist for ulcerative colitis and Crohn's diseasePharmacologic therapy for inflammatory bowel disease refractory to steroidsPatient considerations in the management of ulcerative colitis - role of vedolizumabAdvances in refractory ulcerative colitis treatment: A new therapeutic target, Annexin A2Biologics in the management of ulcerative colitis - comparative safety and efficacy of TNF-α antagonistsInfliximab is superior to other biological agents for treatment of active ulcerative colitis: A meta-analysisAn indirect comparison of infliximab versus adalimumab or golimumab for active ulcerative colitisDesigning biologic selectivity for inflammatory bowel disease--role of vedolizumabGolimumab for the treatment of ulcerative colitis.Tumour necrosis factor superfamily members in the pathogenesis of inflammatory bowel diseaseTargeting α4β7 integrin reduces mucosal transmission of simian immunodeficiency virus and protects gut-associated lymphoid tissue from infection.Introducing vedolizumab to clinical practice: who, when, and how?Systematic Review with Network Meta-Analysis: Comparative Efficacy of Biologics in the Treatment of Moderately to Severely Active Ulcerative ColitisComparative Effectiveness of Infliximab and Adalimumab in Crohn's Disease and Ulcerative Colitis.Fecal calprotectin level correlated with both endoscopic severity and disease extent in ulcerative colitis.Comparative effectiveness and safety of infliximab and adalimumab in patients with ulcerative colitis.Public versus Private Drug Insurance and Outcomes of Patients Requiring Biologic Therapies for Inflammatory Bowel Disease.Vedolizumab: toward a personalized therapy paradigm for people with ulcerative colitis.Surgical management of ulcerative colitis in the era of biologicals.Treatment of IBD: where we are and where we are going.New targeted therapies such as anti-adhesion molecules, anti-IL-12/23 and anti-Janus kinases are looking toward a more effective treatment of inflammatory bowel disease.Ulcerative Colitis: What is the Optimal Treatment Goal and How Do We Achieve It?Progress with anti-tumor necrosis factor therapeutics for the treatment of inflammatory bowel disease.Vedolizumab for the treatment of moderately to severely active ulcerative colitis.Biologic agents for IBD: practical insights.Balancing the risks and benefits of biologic therapy in inflammatory bowel diseases.Vedolizumab for the treatment of ulcerative colitis.New treatment strategies for ulcerative colitis.How Will Evolving Future Therapies and Strategies Change How We Position the Use of Biologics in Moderate to Severely Active Inflammatory Bowel Disease.The Importance of Considering Differences in Study Design in Network Meta-Analysis: An Application Using Anti-Tumor Necrosis Factor Drugs for Ulcerative Colitis.Adalimumab for Moderately to Severely Active Ulcerative Colitis: A Systematic Review and Meta-Analysis.Optimizing Treatment with TNF Inhibitors in Inflammatory Bowel Disease by Monitoring Drug Levels and Antidrug Antibodies.Considerations, challenges and future of anti-TNF therapy in treating inflammatory bowel disease.Safety Profile of Biologic Drugs in the Therapy of Ulcerative Colitis: A Systematic Review and Network Meta-Analysis.Systematic review with meta-analysis: comparative efficacy of biologics for induction and maintenance of mucosal healing in Crohn's disease and ulcerative colitis controlled trials.Golimumab for moderately to severely active ulcerative colitis.
P2860
Q26745725-896FF1FC-B98A-4E35-9E97-306B55A9A58FQ26745782-F2416E4A-7A73-432B-9960-6E3F6D6AA085Q26748626-1DAF53DC-B5E6-472B-9435-CD52B08AF7B0Q26776139-A150B3EB-36B7-4ED2-A932-73C3573FE66FQ26786018-F77212AF-6FA0-49B6-BFF2-1E03CEEE4EB3Q26796415-7954AAFC-3A67-4123-92C2-76668C259368Q26796432-95C45326-6B77-4A41-B28F-CD849D1D17CEQ26798299-BB08D1F3-1260-4AD9-ACCA-38A0ECA164E2Q26999078-1B1E3C43-0BF0-4E54-B80C-7715B2E0145AQ27006683-0C77870C-0658-4DED-8C08-11FE7DE88EEAQ28079322-4A17CD1F-7B35-4375-8B11-3BC440FCD4FCQ28083872-D4305F38-494D-437A-AE9E-43184D8C6340Q33852257-1D21F7DB-A565-4874-9F8B-918145C19B85Q33865593-8F4DF6CB-D54B-4FAD-9462-6A258D3BFA35Q34641933-3E6AAEF9-49E4-411F-BE9B-5D625EA66CACQ35562290-9893CE3C-2CC8-40D0-B7B6-E964A2EF6D3AQ36173188-A4F702C8-AB4A-4D70-87A5-3FA34009ED3AQ36689512-640F016B-FBE8-4F24-99F4-3E13859A344EQ36793729-C6192E0A-317D-4AF2-88A3-72E9A021D23EQ37029359-A32E1838-A425-4B8B-84E3-7D83E1502CECQ37625290-80280682-C569-478A-B92A-B34C27CD0314Q37691599-B4FC1096-57B4-4BD9-969D-D4CA9A859B61Q38249428-8B04DAAB-7504-421E-A5AC-32F06EB460A1Q38285619-4453848E-5537-41E4-928C-431C9096C060Q38293802-4CB9F439-B860-407D-8852-E52B260C1277Q38331566-B8FFBD90-2CC4-4DB4-9811-7EBB17087E6DQ38365049-088C28E6-3D79-4629-A4B0-8D974122D8F3Q38425873-9C67A7AF-176B-491A-8299-0D48948C12C6Q38568898-65D508A6-4651-4A48-9F92-069A57266460Q38630959-098E9A02-CFB1-4775-85FC-98A85F5280ADQ38633318-9769B1F0-C266-4EC0-8FEA-57EAF7DEB54EQ38670811-4AC4C483-1882-4A23-91C4-87C925998BC2Q38719570-B76DD96E-CB72-4F0C-8837-460AF5A4E61AQ38722400-4C48DC83-8718-428C-8656-4594393DEDC7Q38818978-044A68C5-9889-4258-984E-7733997F670BQ38822920-2312CC7E-840B-474A-A01D-4BFD48D5AEFDQ38850063-35FCB731-6672-4C0C-BFEF-FD4EF7D5323AQ38867779-B91A3387-9B68-4D6B-9444-90C4CC32D0D0Q38888227-62BE5F72-9B4D-41CC-A395-B8C8E7CA4C95Q38921072-8B52B9E8-2818-4FDC-87DE-DA1BD1C2635A
P2860
Biological agents for moderately to severely active ulcerative colitis: a systematic review and network meta-analysis.
description
2014 nî lūn-bûn
@nan
2014 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
name
Biological agents for moderate ...... iew and network meta-analysis.
@ast
Biological agents for moderate ...... iew and network meta-analysis.
@en
type
label
Biological agents for moderate ...... iew and network meta-analysis.
@ast
Biological agents for moderate ...... iew and network meta-analysis.
@en
prefLabel
Biological agents for moderate ...... iew and network meta-analysis.
@ast
Biological agents for moderate ...... iew and network meta-analysis.
@en
P50
P356
P1476
Biological agents for moderate ...... iew and network meta-analysis.
@en
P2093
Silvio Danese
Stefanos Bonovas
P304
P356
10.7326/M13-2403
P407
P577
2014-05-01T00:00:00Z